Brian Gallagher Jr.

Brian co-founded Trekk Venture Partners in 2022 where he is a Managing Partner. He has over 25 years of investing, business development, operational and R&D experience in both biotechnology and large pharmaceutical companies. He currently has independent board roles as chairman of the board of eFFECTOR Therapeutics (NASDAQ: EFTR) and non-executive director of Slate Bio. Prior to Trekk, Brian was a Partner and Head of the Boston office at Abingworth, a transatlantic venture capital firm from 2018-2022, where he led investments in and was on the boards of 032 Bio and eFFECTOR. Prior to Abingworth, Brian was a Partner at SR One, the venture capital arm of GlaxoSmithKline (GSK) from 2010-2018, where he led investments in and was on the boards of Aileron Therapeutics (NASDAQ: ALRN), Calcimedica, Constellation Pharmaceuticals (NASDAQ: CNST), Dicerna Pharmaceuticals (NASDAQ: DRNA), Navitor Pharmaceuticals, Nimbus Therapeutics, Princeps Therapeutics, River Vision (acquired by Horizon Pharma), Spero Therapeutics (NASDAQ: SPRO), SpringLeaf Therapeutics, Translate Bio (NASDAQ: TBIO) and numerous other companies.

Prior to SR One, Brian was at Sirtris Pharmaceuticals from 2008-2010 where he was responsible for corporate development, operations and post-merger integration after the company's $720M acquisition by GSK. Prior to Sirtris, Brian held key roles in operations and R&D at Alantos Pharmaceuticals from 2005-2007 which acquired by Amgen for $300M in 2007. Brian started his career as a medicinal chemist and group leader at the Japanese pharmaceutical company Eisai from 1998-2005, where he started and led multiple drug discovery programs in Oncology and Immunology.

Brian holds a PhD in Organic Chemistry from the University of Michigan and a BS in Chemistry from the University of Massachusetts, where he was a Shapiro scholar. He is an inventor on over 25 patents and applications and is the senior author of a number of publications in prominent journals. He currently serves on the Investment Advisory Board for University of Michigan Biomedical Venture Fund (MBVF), and the Advisory Board for Michigan Drug Discovery. Brian was previously on the Advisory Boards of NYU Medical School's Therapeutic Alliances and the National Brain Tumor Society, was a mentor for NVCA Corporate VC Mentorship Program and MassBio's MassCONNECT, and has been a peer reviewer/editorial board member for numerous scientific journals and science research funding authorities.